HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Systemic administration of the di-apocarotenoid norbixin (BIO201) is neuroprotective, preserves photoreceptor function and inhibits A2E and lipofuscin accumulation in animal models of age-related macular degeneration and Stargardt disease.

Abstract
Atrophic A\age-related macular degeneration (AMD) and Stargardt disease (STGD) are major blinding diseases affecting millions of patients worldwide, but no treatment is available. In dry AMD and STGD oxidative stress and subretinal accumulation of N-retinylidene-N-retinylethanolamine (A2E), a toxic by-product of the visual cycle, causes retinal pigment epithelium (RPE) and photoreceptor degeneration leading to visual impairment. Acute and chronic retinal degeneration following blue light damage (BLD) in BALB/c mice and aging of Abca4-/- Rdh8-/- mice, respectively, reproduce features of AMD and STGD. Efficacy of systemic administrations of 9'-cis-norbixin (norbixin), a natural di-apocarotenoid, prepared from Bixa orellana seeds with anti-oxidative properties, was evaluated during BLD in BALB/c mice, and in Abca4-/- Rdh8-/- mice of different ages, following three experimental designs: "preventive", "early curative" and "late curative" supplementations. Norbixin injected intraperitoneally in BALB/c mice, maintained scotopic and photopic electroretinogram amplitude and was neuroprotective. Norbixin chronic oral administration for 6 months in Abca4-/- Rdh8-/- mice following the "early curative" supplementation showed optimal neuroprotection and maintenance of photoreceptor function and reduced ocular A2E accumulation. Thus, norbixin appears promising as a systemic drug candidate for both AMD and STGD treatment.
AuthorsValérie Fontaine, Elodie Monteiro, Mylène Fournié, Elena Brazhnikova, Thinhinane Boumedine, Cécile Vidal, Christine Balducci, Louis Guibout, Mathilde Latil, Pierre J Dilda, Stanislas Veillet, José-Alain Sahel, René Lafont, Serge Camelo
JournalAging (Aging (Albany NY)) Vol. 12 Issue 7 Pg. 6151-6171 (04 07 2020) ISSN: 1945-4589 [Electronic] United States
PMID32255762 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • A2-E (N-retinylidene-N-retinylethanolamine)
  • Neuroprotective Agents
  • Retinoids
  • Carotenoids
  • norbixin
Topics
  • Animals
  • Carotenoids (pharmacology)
  • Drug Monitoring (methods)
  • Electroretinography (methods)
  • Injections, Intraperitoneal
  • Macular Degeneration (drug therapy, metabolism, prevention & control)
  • Mice
  • Neuroprotective Agents (pharmacology)
  • Photoreceptor Cells, Vertebrate (drug effects, metabolism)
  • Retinoids (antagonists & inhibitors, metabolism)
  • Stargardt Disease (drug therapy, metabolism, prevention & control)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: